SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-20-009380
Filing Date
2020-04-21
Accepted
2020-04-21 17:08:01
Documents
5
Effectiveness Date
2020-04-21

Document Format Files

Seq Description Document Type Size
1 DEFA14A nc10007625x2_defa14a.htm DEFA14A 18330
2 nc10007625x2_nc01.jpg GRAPHIC 1359680
3 nc10007625x2_nc02.jpg GRAPHIC 2162399
4 nc10007625x2_nc03.jpg GRAPHIC 555136
5 nc10007625x2_nc04.jpg GRAPHIC 219029
  Complete submission text file 0001140361-20-009380.txt   5153703
Mailing Address 200 BROADWAY, 3RD FLOOR NEW YORK NY 10038
Business Address 200 BROADWAY, 3RD FLOOR NEW YORK NY 10038 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

IRS No.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37635 | Film No.: 20805895
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences